TABLE 2.
Characteristics of 18 Patients at Study Entry
| Characteristic | Value* |
|---|---|
| Age (y) | |
| Mean | 73.1 |
| SD | 6.1 |
| PSA at baseline (ng/mL) | |
| Median | 8.04 |
| IQR | 5.96–24.8 |
| Time between initiation of first-generation ADT and mCRPC status (mo) | |
| Median | 47.5 |
| IQR | 27.0–79.0 |
| Patients with prior local treatment | 14 (78) |
| RP only | 4 (22) |
| RP + ePLND | 3 (17) |
| Exclusive RT only | 5 (28) |
| ePLND + aborted RP + RT | 2 (11) |
| Type of prior systemic therapy before resistance to castration | |
| First-generation ADT | 16 (89) |
| Up-front chemotherapy | 2 (11) |
| ISUP grade group version 8.0 at time of diagnosis | |
| Grade 1 | 2 (11) |
| Grade 2 | 2 (11) |
| Grade 3 | 3 (17) |
| Grade 4 | 6 (33) |
| Grade 5 | 4 (22) |
| Unknown | 1 (6) |
| First-line treatment initiated for mCRPC | |
| Enzalutamide (160 mg daily) | 17 (94) |
| Abiraterone (1,000 mg daily) | 1 (6) |
*
Unless otherwise indicated, values are reported as numbers of patients, with percentages in parentheses.
ADT = androgen deprivation therapy; RP = radical prostatectomy; ePLND = extended pelvic lymph node dissection; RT = radiotherapy; ISUP = International Society of Urological Pathology.